Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 351
Filtrar
1.
J Med Internet Res ; 22(10): e21743, 2020 10 30.
Artículo en Inglés | MEDLINE | ID: mdl-33001829

RESUMEN

BACKGROUND: The COVID-19 outbreak was designated a global pandemic on March 11, 2020. The relationship between vaping and contracting COVID-19 is unclear, and information on the internet is conflicting. There is some scientific evidence that vaping cannabidiol (CBD), an active ingredient in cannabis that is obtained from the hemp plant, or other substances is associated with more severe manifestations of COVID-19. However, there is also inaccurate information that vaping can aid COVID-19 treatment, as well as expert opinion that CBD, possibly administered through vaping, can mitigate COVID-19 symptoms. Thus, it is necessary to study the spread of inaccurate information to better understand how to promote scientific knowledge and curb inaccurate information, which is critical to the health of vapers. Inaccurate information about vaping and COVID-19 may affect COVID-19 treatment outcomes. OBJECTIVE: Using structural topic modeling, we aimed to map temporal trends in the web-based vaping narrative (a large data set comprising web-based vaping chatter from several sources) to indicate how the narrative changed from before to during the COVID-19 pandemic. METHODS: We obtained data using a textual query that scanned a data pool of approximately 200,000 different domains (4,027,172 documents and 361,100,284 words) such as public internet forums, blogs, and social media, from August 1, 2019, to April 21, 2020. We then used structural topic modeling to understand changes in word prevalence and semantic structures within topics around vaping before and after December 31, 2019, when COVID-19 was reported to the World Health Organization. RESULTS: Broadly, the web-based vaping narrative can be organized into the following groups or archetypes: harms from vaping; Vaping Regulation; Vaping as Harm Reduction or Treatment; and Vaping Lifestyle. Three archetypes were observed prior to the emergence of COVID-19; however, four archetypes were identified post-COVID-19 (Vaping as Harm Reduction or Treatment was the additional archetype). A topic related to CBD product preference emerged after COVID-19 was first reported, which may be related to the use of CBD by vapers as a COVID-19 treatment. CONCLUSIONS: Our main finding is the emergence of a vape-administered CBD treatment narrative around COVID-19 when comparing the web-based vaping narratives before and during the COVID-19 pandemic. These results are key to understanding how vapers respond to inaccurate information about COVID-19, optimizing treatment of vapers who contract COVID-19, and possibly minimizing instances of inaccurate information. The findings have implications for the management of COVID-19 among vapers and the monitoring of web-based content pertinent to tobacco to develop targeted interventions to manage COVID-19 among vapers.


Asunto(s)
Cannabidiol/administración & dosificación , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/etiología , Internet/estadística & datos numéricos , Neumonía Viral/epidemiología , Neumonía Viral/etiología , Vapeo/efectos adversos , Vapeo/epidemiología , Cannabidiol/efectos adversos , Cannabidiol/farmacología , Cannabidiol/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/terapia , Humanos , Pandemias , Neumonía Viral/terapia , Fumadores/psicología , Fumadores/estadística & datos numéricos , Medios de Comunicación Sociales , Productos de Tabaco
2.
Praxis (Bern 1994) ; 109(13): 1063-1069, 2020.
Artículo en Alemán | MEDLINE | ID: mdl-33050810

RESUMEN

Vaping-Associated Pulmonary Illness Abstract. Electronic cigarettes are hand-held devices used to vaporize liquids by heating and thus allowing inhalation of aerosols. Recently, cases of patients have been published which presented with a syndrome associated with e-cigarette consumption, also known as vaping. The syndrome designated 'vaping-associated pulmonary illness' (VAPI) features either isolated respiratory, or combined respiratory gastro-intestinal or constitutional symptoms. VAPI can be rapidly progressive and lead to severe respiratory failure requiring intensive care treatment. Despite the as yet very incomplete understanding of the causative agents and pathogenesis we review the current knowledge of the clinical, pathological and radiological aspects in VAPI and summarise the current therapeutic strategies.


Asunto(s)
Sistemas Electrónicos de Liberación de Nicotina , Enfermedades Pulmonares , Vapeo , Humanos , Pulmón , Enfermedades Pulmonares/etiología , Vapeo/efectos adversos
4.
J Am Heart Assoc ; 9(18): e017368, 2020 09 15.
Artículo en Inglés | MEDLINE | ID: mdl-32896206

RESUMEN

E-cigarette or vaping product use-associated lung injury was recognized in the United States in the summer of 2019 and is typified by acute respiratory distress, shortness of breath, chest pain, cough, and fever, associated with vaping. It can mimic many of the manifestations of coronavirus disease 2019 (COVID-19). Some investigators have suggested that E-cigarette or vaping product use-associated lung injury was due to tetrahydrocannabinol or vitamin E acetate oil mixed with the electronic cigarette liquid. In experimental rodent studies initially designed to study the effect of electronic cigarette use on the cardiovascular system, we observed an E-cigarette or vaping product use-associated lung injury-like condition that occurred acutely after use of a nichrome heating element at high power, without the use of tetrahydrocannabinol, vitamin E, or nicotine. Lung lesions included thickening of the alveolar wall with foci of inflammation, red blood cell congestion, obliteration of alveolar spaces, and pneumonitis in some cases; bronchi showed accumulation of fibrin, inflammatory cells, and mucus plugs. Electronic cigarette users should be cautioned about the potential danger of operating electronic cigarette units at high settings; the possibility that certain heating elements may be deleterious; and that E-cigarette or vaping product use-associated lung injury may not be dependent upon tetrahydrocannabinol, vitamin E, or nicotine.


Asunto(s)
Dronabinol/toxicidad , Cigarrillo Electrónico a Vapor/toxicidad , Sistemas Electrónicos de Liberación de Nicotina , Lesión Pulmonar/inducido químicamente , Pulmón/efectos de los fármacos , Neumonía/inducido químicamente , Vapeo/efectos adversos , Vitamina E/toxicidad , Animales , Exposición por Inhalación , Pulmón/patología , Lesión Pulmonar/patología , Modelos Animales , Aceites , Neumonía/patología , Ratas , Medición de Riesgo
6.
PLoS One ; 15(9): e0238140, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32881943

RESUMEN

Vitamin E acetate (VEA) is strongly linked to the outbreak of electronic-cigarette or vaping product use-associated lung injury (EVALI). It has been proposed that VEA decomposition to ketene-a respiratory poison that damages lungs at low ppm levels-may play a role in EVALI. However, there is no information available on the temperature at which VEA decomposes and how this correlates with the vaping process. We have studied the temperature-dependent kinetics of VEA decomposition using quantum chemical and statistical mechanical modelling techniques, developing a chemical kinetic model of the vaping process. This model predicts that, under typical vaping conditions, the use of VEA contaminated e-cigarette products is unlikely to produce ketene at harmful levels. However, at the high temperatures encountered at low e-cigarette product levels, which produce 'dry hits', ketene concentrations are predicted to reach acutely toxic levels in the lungs (as high as 30 ppm). We therefore hypothesize that dry hit vaping of e-cigarette products containing VEA contributes to EVALI.


Asunto(s)
Etilenos/metabolismo , Cetonas/metabolismo , Lesión Pulmonar/patología , Vapeo/efectos adversos , Vitamina E/metabolismo , Etilenos/química , Etilenos/toxicidad , Humanos , Cetonas/química , Cetonas/toxicidad , Cinética , Lesión Pulmonar/inducido químicamente , Temperatura , Vitamina E/química
7.
Pediatrics ; 146(4)2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32968029

RESUMEN

In this report, we describe the case of a 17-year-old boy with progressive respiratory failure requiring extracorporeal support who met clinical criteria for a presumptive diagnosis of electronic cigarette or vaping-associated acute lung injury (EVALI), with clinical, pathologic, and laboratory evidence of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). The patient in our report had a history of tetrahydrocannabinol and nicotine electronic cigarette use for months leading up to his presentation of fever, headache, emesis, and weight loss with respiratory distress. Multiple potential diagnoses were explored, and the patient's respiratory status improved, and he was initially discharged from the hospital. Roughly one week later, the patient was readmitted for worsening respiratory distress. The patient then met sufficient criteria for a potential diagnosis of HLH and MAS (elevated ferritin level, inflammatory markers, and cytopenia) to warrant a bone marrow aspirate, which revealed rare hemophagocytic cells. Given the severity of his symptoms and laboratory evidence of HLH and MAS, the patient was started on a course of steroids and anakinra. Although laboratory markers improved after treatment, the patient's respiratory failure worsened, ultimately progressing to a need for mechanical ventilation and extracorporeal support and leading to worsening multiorgan system failure and, ultimately, death. To the best of our knowledge, this is the first report of a patient with a presumptive diagnosis of EVALI with evidence of HLH and MAS, raising the possibility that macrophage activation may play a role in the pathogenesis of EVALI.


Asunto(s)
Lesión Pulmonar Aguda/inducido químicamente , Sistemas Electrónicos de Liberación de Nicotina , Linfohistiocitosis Hemofagocítica/inducido químicamente , Vapeo/efectos adversos , Adolescente , Resultado Fatal , Humanos , Síndrome de Activación Macrofágica/inducido químicamente , Masculino , Insuficiencia Multiorgánica/etiología
8.
PLoS One ; 15(9): e0237938, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32877429

RESUMEN

BACKGROUND: More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy. OBJECTIVE: To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use. DESIGN: Cohort study of US sample, with annual follow-up. PARTICIPANTS: US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443). EXPOSURES: Use of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2. ANALYSIS: Propensity score matching (PSM) of groups using different methods to quit. OUTCOME MEASURES: 12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome. RESULTS: Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products. LIMITATIONS: The frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA. CONCLUSION: Among US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.


Asunto(s)
Fumar Cigarrillos/efectos adversos , Quimioterapia/estadística & datos numéricos , Sistemas Electrónicos de Liberación de Nicotina/estadística & datos numéricos , Cese del Hábito de Fumar/métodos , Tabaquismo/terapia , Vapeo/efectos adversos , Adolescente , Adulto , Terapia Conductista , Fumar Cigarrillos/psicología , Femenino , Humanos , Incidencia , Estudios Longitudinales , Masculino , Cese del Hábito de Fumar/psicología , Factores de Tiempo , Dispositivos para Dejar de Fumar Tabaco/efectos adversos , Tabaquismo/epidemiología , Tabaquismo/etiología , Estados Unidos/epidemiología , Adulto Joven
9.
J Adolesc Health ; 67(4): 519-523, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32798097

RESUMEN

PURPOSE: This study aimed to assess whether youth cigarette and electronic cigarette (e-cigarette) use are associated with coronavirus disease 2019 (COVID-19) symptoms, testing, and diagnosis. METHODS: An online national survey of adolescents and young adults (n = 4,351) aged 13-24 years was conducted in May 2020. Multivariable logistic regression assessed relationships among COVID-19-related symptoms, testing, and diagnosis and cigarettes only, e-cigarettes only and dual use, sociodemographic factors, obesity, and complying with shelter-in-place. RESULTS: COVID-19 diagnosis was five times more likely among ever-users of e-cigarettes only (95% confidence interval [CI]: 1.82-13.96), seven times more likely among ever-dual-users (95% CI: 1.98-24.55), and 6.8 times more likely among past 30-day dual-users (95% CI: 2.40-19.55). Testing was nine times more likely among past 30-day dual-users (95% CI: 5.43-15.47) and 2.6 times more likely among past 30-day e-cigarette only users (95% CI: 1.33-4.87). Symptoms were 4.7 times more likely among past 30-day dual-users (95% CI: 3.07-7.16). CONCLUSIONS: COVID-19 is associated with youth use of e-cigarettes only and dual use of e-cigarettes and cigarettes, suggesting the need for screening and education.


Asunto(s)
Conducta del Adolescente , Fumar Cigarrillos/efectos adversos , Infecciones por Coronavirus/etiología , Neumonía Viral/etiología , Vapeo/efectos adversos , Adolescente , Betacoronavirus , Fumar Cigarrillos/epidemiología , Estudios Transversales , Sistemas Electrónicos de Liberación de Nicotina , Femenino , Humanos , Masculino , Pandemias , Factores de Riesgo , Encuestas y Cuestionarios , Vapeo/epidemiología , Adulto Joven
11.
Rev Med Suisse ; 16(703): 1511-1517, 2020 Aug 26.
Artículo en Francés | MEDLINE | ID: mdl-32852174

RESUMEN

Vaping associated lung injury is defined by a compatible clinical and radiological picture in a patient who smoked an electronic cigarette in the previous 90 days and after exclusion of other conditions, -notably infections. The severity varies from mild symptoms to -hypoxemic respiratory failure eventually leading to death. The clinical presentation includes general, respiratory and gastrointestinal symptoms. Laboratory findings show leukocytosis with elevated -inflammatory markers. Radiological features consist of bilateral ground-glass opacities with or without consolidation. Broncho-alveolar lavage can be used to refine the diagnosis and exclude an infection. Corticosteroids are at the center of therapy. Antibiotics are often given because of the initial suspicion of infection.


Asunto(s)
Sistemas Electrónicos de Liberación de Nicotina , Enfermedades Pulmonares , Lesión Pulmonar , Vapeo , Humanos , Lesión Pulmonar/etiología , Tomografía Computarizada por Rayos X , Vapeo/efectos adversos
12.
PLoS One ; 15(8): e0238172, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32845911

RESUMEN

E-cigarette devices are wide ranging, leading to significant differences in levels of toxic carbonyls in their respective aerosols. Power can be a useful method in predicting relative toxin concentrations within the same device, but does not correlate well to inter-device levels. Herein, we have developed a simple mathematical model utilizing parameters of an e-cigarette's coil and wick in order to predict relative levels of e-liquid solvent degradation. Model 1, which is coil length/(wick surface area*wraps), performed in the moderate-to-substantial range as a predictive tool (R2 = 0.69). Twelve devices, spanning a range of coil and wick styles, were analyzed. Model 1 was evaluated against twelve alternative models and displayed the best predictability. Relationships that included power settings displayed weak predictability, validating that power levels cannot be reliably compared between devices due to differing wicking and coil components and heat transfer efficiencies.


Asunto(s)
Aerosoles/química , Compuestos Inorgánicos de Carbono/análisis , Sistemas Electrónicos de Liberación de Nicotina , Vapeo/efectos adversos , Humanos , Modelos Teóricos
13.
Orv Hetil ; 161(31): 1281-1285, 2020 08.
Artículo en Húngaro | MEDLINE | ID: mdl-32750017

RESUMEN

The electronic cigarette and vaping associated lung injury (EVALI) syndrome was first described in the United States (US) and was presumably strongly associated with cannabinoid vaping and exposure to vitamin E acetate, an oily additive used to dilute/cut cannabinoids vape liquids. As the case numbers were relatively low (epidemiologically) and the available data was inconsistent, several assumptions were made to explain the phenomenon. The lack of standardization of sampling, the self-reported, inhomogeneous user habits, the huge number of potential etiologies, and certain trade/legal loopholes (such as online distribution, black market penetration, or the inefficient regulatory control regarding the quantity and/or quality of ingredients/cutting agents) might question the validity of the data and the consequent conclusions. Furthermore, an interesting but by no means negligible question is the fact why no EVALI cases have been registered outside the US when electronic cigarettes and vapes have become increasingly popular worldwide. The present review seeks to answer whether vitamin E acetate is indeed the cause of this complex syndrome, what potentially non-healthcare related factors might have contributed to the rapid increase and decline in EVALI cases, and last but not least the minimum standards of safe vaping (as potential for drug delivery route for cannbinoids). Orv Hetil. 2020; 161(31): 1281-1285.


Asunto(s)
Cannabinoides/efectos adversos , Sistemas Electrónicos de Liberación de Nicotina , Lesión Pulmonar/inducido químicamente , Vapeo/efectos adversos , Cannabinoides/administración & dosificación , Humanos , Autoinforme , Estados Unidos , Vitamina E
14.
Artículo en Inglés | MEDLINE | ID: mdl-32635510

RESUMEN

E-cigarettes may have a role in supporting pregnant women who would otherwise smoke to stop smoking. The study aimed to understand pregnant women's vaping experiences, in particular how vaping to stop smoking is facilitated and how barriers to this are overcome. We conducted semi structured telephone interviews (n = 15) with pregnant or postpartum women who vaped during pregnancy, either exclusively (n = 10) or dual-used (n = 5) (smoked and vaped). Thematic analysis was used to analyse the interviews. Two themes emerged. First, 'facilitating beliefs': inherent beliefs that helped women overcome barriers to vaping. These included understanding the relative safety of vaping and economic gains compared with smoking and pregnancy being a motivator to stop smoking. Second, 'becoming a confident vaper': accumulating sufficient skill and confidence to comfortably vape. This included experimentation with e-cigarettes to ensure nicotine dependence and sensory needs were met. Seeking social support and employing strategies to address social stigma were also important. Positive beliefs about vaping and becoming proficient at vaping were viewed as ways to overcome barriers to vaping. The theoretical domain framework informed intervention recommendations to assist pregnant smokers who have tried but cannot stop smoking to switch to vaping.


Asunto(s)
Sistemas Electrónicos de Liberación de Nicotina , Mujeres Embarazadas/psicología , Cese del Hábito de Fumar/psicología , Fumar/efectos adversos , Vapeo/efectos adversos , Adulto , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Entrevistas como Asunto , Embarazo , Investigación Cualitativa , Fumadores , Fumar/psicología , Teléfono
15.
Anesthesiology ; 133(4): 948-949, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-32675690
17.
Am J Physiol Lung Cell Mol Physiol ; 319(4): L585-L595, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-32726146

RESUMEN

In 2019, the United States experienced the emergence of the vaping-associated lung injury (VALI) epidemic. Vaping is now known to result in the development and progression of severe lung disease in the young and healthy. Lack of regulation on electronic cigarettes in the United States has resulted in over 2,000 patients and 68 deaths. We examine the clinical representation of VALI and the delve into the scientific evidence of how deadly exposure to electronic cigarettes can be. E-cigarette vapor is shown to affect numerous cellular processes, cellular metabolism, and cause DNA damage (which has implications for cancer). E-cigarette use is associated with a higher risk of developing crippling lung conditions such as chronic obstructive pulmonary disease (COPD), which would develop several years from now, increasing the already existent smoking-related burden. The role of vaping and virus susceptibility is yet to be determined; however, vaping can increase the virulence and inflammatory potential of several lung pathogens and is also linked to an increased risk of pneumonia. As it has emerged for cigarette smoking, great caution should also be given to vaping in relation to SARS-CoV-2 infection and the COVID-19 pandemic. Sadly, e-cigarettes are continually promoted and perceived as a safer alternative to cigarette smoking. E-cigarettes and their modifiable nature are harmful, as the lungs are not designed for the chronic inhalation of e-cigarette vapor. It is of interest that e-cigarettes have been shown to be of no help with smoking cessation. A true danger lies in vaping, which, if ignored, will lead to disastrous future costs.


Asunto(s)
Cigarrillo Electrónico a Vapor/toxicidad , Enfermedades Pulmonares Intersticiales/epidemiología , Lesión Pulmonar/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Vapeo/efectos adversos , Adolescente , Betacoronavirus , Infecciones por Coronavirus/patología , Susceptibilidad a Enfermedades/inducido químicamente , Sistemas Electrónicos de Liberación de Nicotina/estadística & datos numéricos , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/inducido químicamente , Lesión Pulmonar/inducido químicamente , Lesión Pulmonar/mortalidad , Masculino , Persona de Mediana Edad , Pandemias , Neumonía/epidemiología , Neumonía Viral/patología , Enfermedad Pulmonar Obstructiva Crónica/inducido químicamente , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Cese del Hábito de Fumar/métodos , Estados Unidos/epidemiología , Vapeo/epidemiología , Vapeo/mortalidad
18.
Life Sci ; 257: 118084, 2020 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-32663572

RESUMEN

Since an outbreak of vaping-related deaths in the US has been reported as a public health crisis, the cardiovascular safety of nicotine nowadays receives increasing attention due to use of tobacco cigarette alternatives, such as electronic cigarettes. However, whether and how nicotine contributes to cardiac detrimental effects are in great controversy, especially less understood in young adult population. We report that chronic nicotine exposure, a major component of Electronic cigarettes, resulted in directly inhibited cardiomyocytes viability, increased cardiac fibrosis, and markedly suppressed cardiac function compared with sham. Gene array combined with bioinformatics analysis identified cardiac apoptosis and mitophagy were the key signals responsible for nicotine induced cardiac detrimental effect. Mechanistically, nicotine exposure markedly increased cleaved Caspase 3 and cleaved Caspase 9 indicating the involvement of intrinsic apoptotic pathway (mitochondrial cell death pathway). Meanwhile, nicotine-induced ROS outbreak promoted lysomal alkalization, furthermore blocked mitophagic degradation, thereby disrupted mitophagic flux promoted mitochondrial cell death cascade. Taken together, these findings indicate that nicotine confers cardiotoxicity via ROS-induced mitophagic flux blockage and provide the first demonstration of a causative link between nicotine and cardiac toxicity in young adult rat which may suggest nicotine induces cardiomyocytes impairment leading to cardiotoxicity in young adult population.


Asunto(s)
Apoptosis/efectos de los fármacos , Cardiotoxicidad/etiología , Mitofagia/efectos de los fármacos , Miocitos Cardíacos/efectos de los fármacos , Nicotina/toxicidad , Animales , Cardiotoxicidad/fisiopatología , Sistemas Electrónicos de Liberación de Nicotina , Mitocondrias/efectos de los fármacos , Mitocondrias/patología , Miocitos Cardíacos/patología , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Vapeo/efectos adversos
19.
J Cardiovasc Pharmacol Ther ; 25(6): 578-586, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32691614

RESUMEN

BACKGROUND: Smoking is the main preventable cause of death in the United States and worldwide and is associated with serious cardiovascular health consequences, including thrombotic diseases. Recently, electronic cigarettes (e-cigarettes) and, in particular JUUL, have attained wide popularity among smokers, nonsmokers, pregnant females, and even the youth, which is alarming. Interestingly, there is/are no information/studies regarding the effect of JUUL on cardiovascular diseases, specifically in the context of modulation of platelet activation. Thus, it is important to discern the cardiovascular disease health risks associated with JUUL. METHODS AND RESULTS: We used a passive e-vape vapor inhalation system where C57BL/6J mice (10-12 weeks old) were exposed to JUUL e-cigarette vape. Menthol flavored JUUL pods containing 5% nicotine by weight were used as the e-liquid. Mice were exposed to a total of 70 puffs daily for 2 weeks; 3-second puff duration, and 25-second puff interval. The effects of JUUL relative to clean air were analyzed, on mouse platelet function in vitro (eg, aggregation) and in vivo (eg, FeCl3-induced carotid artery injury thrombosis model). Our results indicate that short-term exposure to JUUL e-cigarette causes hyperactivation of platelets and shortens the thrombus occlusion as well as hemostasis/bleeding times, relative to clean air (medians of 14 vs. 200 seconds, P < .01 and 35 vs. 295 seconds, P < .001, respectively). CONCLUSION: Our findings document-for the first time-that short-term exposure to the JUUL e-cigarette increases the risk of thrombotic events, in part by modulating platelet function, such as aggregation and secretion, in mice.


Asunto(s)
Plaquetas/metabolismo , Trombosis de las Arterias Carótidas/etiología , Cigarrillo Electrónico a Vapor/efectos adversos , Sistemas Electrónicos de Liberación de Nicotina , Activación Plaquetaria , Vapeo/efectos adversos , Animales , Trombosis de las Arterias Carótidas/sangre , Modelos Animales de Enfermedad , Masculino , Ratones Endogámicos C57BL , Fosfatidilserinas/sangre , Agregación Plaquetaria , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Transducción de Señal , Vapeo/sangre
20.
Artículo en Inglés | MEDLINE | ID: mdl-32708854

RESUMEN

Measures of tobacco product harm perceptions are important in research, given their association with tobacco use. Despite recommendations to use more specific harm and risk perception measures, limited research exists comparing different wordings. We present exploratory survey data comparing young adults' (ages 18-29) responses to a general e-cigarette harm perception measure ("How harmful, if at all, do you think vaping/using an e-cigarette is to a user's health?") with a more specific conditional measure, which personalized the behavior/harm ("imagine you vaped," "your health") and presented a specific use condition (exclusive daily vaping) and timeframe (10 years). Data were collected in January 2019 (n = 1006). Measures were highly correlated (r = 0.76, Cronbach's α = 0.86), and most (65%) provided consistent responses, although more participants rated e-cigarettes as very or extremely harmful using the conditional (51.6%) versus the general (43.9%) harm measure. However, significant differences in harm ratings were not observed among young adults who currently vaped. Correlations between each harm perception measure and measures of e-cigarette use intentions were similar. More specifically worded harm perception measures may result in somewhat higher e-cigarette harm ratings than general measures for some young adults. Additional research on best practices for measuring e-cigarette and other tobacco harm perceptions is warranted.


Asunto(s)
Sistemas Electrónicos de Liberación de Nicotina , Opinión Pública , Productos de Tabaco , Vapeo , Adolescente , Adulto , Humanos , Riesgo , Encuestas y Cuestionarios , Tabaco , Vapeo/efectos adversos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA